Annual Report And Accounts

Overview

The report describes 2025 Phase 3 Orbit and Cosmic results in which the primary fracture-rate endpoints were not statistically significant, although secondary bone mineral density endpoints were achieved. It reports £0.4 million of revenue from a leflutroazole clinical milestone payment. The company reports 39 employees at December 31, 2025 and environmental data of 72,376 KWH of energy use and 13 tCO2e of associated emissions.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services